Castle Biosciences INC Form 4 insider transactions

Director Rodney Cotton amended his Form 4 filing to report the acquisition of 6,721 Restricted Stock Units (RSUs) in Castle Biosciences, vesting on May 23, 2025.

Director Rodney Cotton acquired 6,777 Restricted Stock Units in Castle Biosciences, vesting in equal annual installments starting May 23, 2025.

Castle Biosciences CEO Derek Maetzold sold shares of the company's common stock on March 7th and March 10th, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Kristen Oelschlager, COO of Castle Biosciences, reports acquisition and disposal of common stock and restricted stock units.

Castle Biosciences CEO Derek J. Maetzold reported the acquisition and disposal of common stock and restricted stock units, executed under a pre-arranged 10b5-1 trading plan.

Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences, reports acquisition and disposal of company stock and restricted stock units on March 4, 2025.

Frank Stokes, CFO of Castle Biosciences, reports the acquisition and disposal of company stock and restricted stock units.

Frank Stokes, CFO of Castle Biosciences, sold 8,046 shares of common stock at an average price of $26.70 on February 20, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Director Daniel Bradbury and related trusts sold shares of Castle Biosciences (CSTL) common stock on February 5, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold executed sales of common stock on January 13, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Director Daniel Bradbury of Castle Biosciences sold a total of 13,291 shares of common stock on January 6, 2025, through a pre-arranged 10b5-1 trading plan.

Castle Biosciences CEO, Derek J. Maetzold, executed multiple sales of company stock through various trusts under a pre-arranged 10b5-1 trading plan.

A Castle Biosciences executive, Tobin W. Juvenal, sold 2,230 shares of common stock at $30 per share under a pre-arranged 10b5-1 trading plan.

Derek Maetzold, CEO of Castle Biosciences, sold a portion of his holdings in company stock on December 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO, Derek Maetzold, executed multiple sales of company stock through various trusts under a pre-arranged 10b5-1 trading plan.

A Castle Biosciences executive, Juvenal Tobin, engaged in multiple transactions involving common stock and restricted stock units, including both acquisitions and disposals.

Castle Biosciences CEO, Derek Maetzold, reports the acquisition and disposal of company stock and restricted stock units through various transactions and trusts.

Castle Biosciences' Chief Financial Officer, Frank Stokes, has reported multiple transactions involving the company's stock, including the vesting and sale of restricted stock units.

Castle Biosciences' Chief Operating Officer, Kristen Oelschlager, has reported multiple transactions involving the company's common stock and restricted stock units.

Castle Biosciences CEO, Derek J. Maetzold, executed multiple sales of common stock under a pre-arranged 10b5-1 trading plan.

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on December 3, 2024, under a pre-arranged 10b5-1 trading plan.

Castle Biosciences' Chief Financial Officer, Frank Stokes, sold a total of 6,923 shares of common stock on November 15, 2024, under a pre-arranged 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold executed multiple sales of company stock on November 12, 2024, under a pre-arranged 10b5-1 trading plan.

Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Derek Maetzold, CEO of Castle Biosciences, executed multiple sales of common stock on November 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences, exercised stock options and sold shares of common stock on November 1, 2024, according to a Form 4 filing with the SEC.

Director Daniel Bradbury of Castle Biosciences sold shares of the company's common stock on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold executed sales of common stock on October 14, 2024, through a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences' CEO, Derek Maetzold, executed multiple sales of common stock on October 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on October 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.